Literature DB >> 7566335

Networking with proline-directed protein kinases implicated in tau phosphorylation.

S L Pelech1.   

Abstract

Proline-directed kinases such as the mitogen-activated protein (MAP) kinases, cyclin-dependent protein kinase 5 (CDK5) and glycogen synthase 3 (GSK3) have been implicated in the hyperphosphorylation of the tau protein associated with Alzheimer's disease. Such aberrant phosphorylation of tau appears to compromise on its ability to bind to and stabilize microtubules, and this may contribute to Alzheimer's disease pathology. In this review, the architecture of the intracellular signal transduction pathways that regulate proline-directed kinases is described. The MAP kinases serve as major intersection points in the flow of information from a plethora of extracellular stimuli and affect diverse cellular processes that are often important for cell proliferation. Although brain contains terminally differentiated neurons, many of the known components of MAP kinase-dependent lines of communication are highly expressed in the nervous system. Similar signalling pathways may also regulate CDK5 and GSK3. In mitotic cells, abnormal activation of the protein kinase network at multiple points can contribute to oncogenic transformation. It is proposed that Alzheimer's disease may also result from accumulated defects in the kinase network that governs the proline-directed kinases such that their inappropriate activation is sustained in the affected neurons. A detailed understanding of proline-directed kinase-dependent pathways may permit the identification of rational targets for the therapeutic intervention of Alzheimer's disease and other neurological disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7566335     DOI: 10.1016/0197-4580(94)00187-6

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  21 in total

1.  Cloning and characterization of murine glial cell-derived neurotrophic factor inducible transcription factor (MGIF).

Authors:  S Yajima; C H Lammers; S H Lee; Y Hara; K Mizuno; M M Mouradian
Journal:  J Neurosci       Date:  1997-11-15       Impact factor: 6.167

2.  Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry.

Authors:  Henrik Molina; David M Horn; Ning Tang; Suresh Mathivanan; Akhilesh Pandey
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-07       Impact factor: 11.205

3.  CR16, a novel proline-rich protein expressed in rat brain neurons, binds to SH3 domains and is a MAP kinase substrate.

Authors:  M C Weiler; J L Smith; J N Masters
Journal:  J Mol Neurosci       Date:  1996       Impact factor: 3.444

Review 4.  Role of MAP kinase in neurons.

Authors:  K Fukunaga; E Miyamoto
Journal:  Mol Neurobiol       Date:  1998-02       Impact factor: 5.590

5.  Neurotrophins stimulate phosphorylation of synapsin I by MAP kinase and regulate synapsin I-actin interactions.

Authors:  J N Jovanovic; F Benfenati; Y L Siow; T S Sihra; J S Sanghera; S L Pelech; P Greengard; A J Czernik
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

Review 6.  Roles of AMP-activated protein kinase in Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Keshen Li; Sohel H Quazi; Bin Zhao
Journal:  Neuromolecular Med       Date:  2012-02-26       Impact factor: 3.843

7.  Listeria monocytogenes invasion of epithelial cells requires the MEK-1/ERK-2 mitogen-activated protein kinase pathway.

Authors:  P Tang; C L Sutherland; M R Gold; B B Finlay
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

8.  Stress-induced tau phosphorylation in mouse strains with different brain Erk 1 + 2 immunoreactivity.

Authors:  A Y Korneyev
Journal:  Neurochem Res       Date:  1998-12       Impact factor: 3.996

Review 9.  Dephosphorylating eukaryotic RNA polymerase II.

Authors:  Joshua E Mayfield; Nathaniel T Burkholder; Yan Jessie Zhang
Journal:  Biochim Biophys Acta       Date:  2016-01-15

Review 10.  Mechanism-based treatments for Alzheimer's disease.

Authors:  Peter Davies; Jeremy Koppel
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.